2 cheap shares I’ve spotted in my July bargain hunt

Jon Smith thinks he’s spotted a couple of cheap shares based on recent share price falls and the subsequent valuation metrics.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At the beginning of each month, I always check my different stock market filters. Some of these are set up for screening top dividend shares, others more for growth. Yet one I always check is for companies that have fallen in value, with a low price-to-earnings ratio. As such, this aims to filter for cheap shares that I can consider buying for the new month.

A reputational wobble

One that has popped up is GSK (LSE:GSK). The pharma giant saw the share price drop 14% last month which acted to push the price-to-earnings ratio below 10 (my fair value benchmark).

Most of the drop came at the start of the month with news regarding its Zantac heartburn drug legal case. Around 70,000 cases have been brought forward claiming that the drug causes cancer, which if proven would have large reputational and financial implications. The stock dropped by 10% after the court ruled that jury trials could hear expert witnesses as part of the trial.

Even though this situation is a risk, I think the stock has overreacted. The business has been around for decades and has successfully navigated problems like this in the past. I don’t see this being an issue if we fast forward a year. Even when I zoom out from the one month performance, I can see the stock’s still up 9% over the past year.

Further, GSK’s a profitable company that’s growing year on year. For example, versus 2022, the firm increased revenue, operating profit and pre-tax profit last year. This also helps the dividend payments. With a yield just shy of 4%, I think this could be a cheap share to snap up to benefit from both share price gains and income.

Another option on my radar is Jupiter Asset Management (LSE:JUP). The stock dropped 11% over the last month, bringing the loss over the past year to 28%.

The business has struggled with the tough macro environment in recent years, alongside tougher competition in the investment management space. However, there comes a point where I think this becomes too cheap to ignore.

After all, total assets under management from Q1 increased to £52.6bn from £52.2bn the previous quarter. A good chunk of this was driven by positive market returns of the funds. Ultimately, the higher the assets under management figure is, the more fee driven revenue and commission Jupiter can earn.

I like the company because even with the difficulties that the whole sector has dealt with, it’s still profitable. Given that fact, I can still use the price-to-earnings ratio to get a feel for value. It’s currently at 5.22.

Of course, the risk here is that I buy now but the trend is still lower for the share price over the next year before it starts to rally. This is possible, but I struggle to see how much lower this can go, given that there are zero signs that the company is going bust anytime soon.

Overall, I’m thinking about buying both shares as we start the month.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jon Smith has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK and Jupiter Fund Management Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing For Beginners

Investing Articles

What would I do if Rolls-Royce shares plunged 50%? History suggests a big decline is coming

While Rolls-Royce shares have delivered massive outperformance in recent years, they also have a history of significant declines.

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

2 of the widest moats in the FTSE 100

A durable competitive advantage is key to a good investment. And Stephen Wright thinks a couple of FTSE 100 firms…

Read more »

Investing Articles

Will the 5.6% BT Group dividend yield grow in 2024?

Zaven Boyrazian explores whether BT Group can continue hiking its dividend and if the telecoms giant belongs in his income…

Read more »

Investing Articles

FTSE 100’s near a 52-week high, but this stock’s still dirt cheap!

The FTSE 100's on the rise, but not all stocks have been so fortunate. Here’s one company that got left…

Read more »

Investing Articles

£3,000 of savings? Here’s how I’d use that to start buying shares this July

Our writer uses his investment experience to consider what he would do today if he wanted to start buying shares…

Read more »

Investing Articles

Would I be crazy to buy Lloyds shares at a 52-week high?

Lloyds shares are up 30% over the last 12 months. But at a P/E ratio of 8, is it too…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

History suggests the FTSE 100 may double from where it is now

The FTSE 100 overall is buoyant, but this single stock has the potential to be a better buy now its…

Read more »

Fans of Warren Buffett taking his photo
Investing For Beginners

How to invest £2k the Warren Buffett way

Warren Buffett's made a fortune by investing his money in a very specific way. Here’s how to invest a few…

Read more »